InnoCan Pharma Corporation announced that test results of its unique cannabidiol (CBD) loaded liposomal platform technology developed under the Company's previously announced funded research agreement with Yissum Research and Development Company, the commercial arm of Hebrew University (Jerusalem) demonstrated high loading of CBD, having the potential of a new way of administration by injection. The technology is the subject of a previously announced provisional patent application. Development efforts and tests for the CBD loaded liposomes were performed over several months by Prof. Chezy Barenholz, Head of Membrane and Liposome Research Lab, Hebrew University Hadassah Medical School, Jerusalem and head researcher and supervisor under the Yissum Agreement and the following results were achieved: High loading of CBD was achieved. The loaded amount is sufficient for administration of a therapeutic dose. Several types of CBD liposomal formulations were developed having potential of targeting a variety of clinical indications for CBD injection administration. The liposomal formulations may have the potential to enable a controlled release delivery of injectable CBD. InnoCan's project with Yissum is targeted at developing a breakthrough technology platform that enables the delivery of cannabinoids by injection of hydrogel- cannabinoid-loaded (such as CBD) liposomes into the blood stream or to a specific body part. The controlled release of CBD (or other cannabinoids) from the liposomes may allow continuous exposure of the patient to the cannabinoid and decreases the variations of CBD concentration in the blood caused by food intake or other physiological condition. Moreover, through injection of loaded liposomes, a greater portion of intact CBD can reach its target site, decreasing the total amount of CBD needed to achieve the desired therapeutic effect. The use of the technology is versatile and may be tailored to the development of different cannabinoids.